US Stock MarketDetailed Quotes
AKRO Akero Therapeutics
- 32.275
- +0.105+0.33%
Trading Nov 29 12:28 ET
2.25BMarket Cap-8538P/E (TTM)
32.680High32.000Low94.72KVolume32.350Open32.170Pre Close3.07MTurnover0.17%Turnover RatioLossP/E (Static)69.80MShares37.00052wk High3.05P/B1.77BFloat Cap15.32052wk Low--Dividend TTM54.92MShs Float58.380Historical High--Div YieldTTM2.11%Amplitude7.520Historical Low32.369Avg Price1Lot Size
About Akero Therapeutics Company
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
Company Profile
SymbolAKRO
Company NameAkero Therapeutics
Listing DateJun 20, 2019
Issue Price16.00
Founded2017
CEODr. Andrew Cheng, M.D.,PhD
MarketNASDAQ
Employees56
Fiscal Year Ends12-31
Address601 Gateway Boulevard,Suite 350
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080-7006
Phone1-650-487-6488
Websitehttp://www.akerotx.com
Company Executives
- Name
- Position
- Salary
- Dr. Andrew Cheng, M.D.,PhD
- President, Chief Executive Officer and Director
- 8.83M
- William R. White, J.D.
- Principal Accounting Officer, Executive Vice President, Treasurer, Chief Financial Officer and Head, Corporate Development
- 4.29M
- Dr. Jonathan Young, J.D.
- Executive Vice President, Chief Operating Officer and Secretary
- 3.44M
- Dr. Timothy Rolph, D.Phil.
- Chief Scientific Officer
- 3.49M
- Catriona Yale
- Chief Development Officer
- 3.45M
- Patrick Lamy
- Senior Vice President, Commercial Strategy
- --
- Mark T. Iwicki
- Chairman of the Board
- 606.06K
- Dr. Graham Waley, M.D.,PhD
- Independent Director
- 578.56K
- Tomas J. Heyman
- Independent Director
- 581.06K
- Jane Pritchett Henderson
- Independent Director
- 586.06K
- Dr. Seth L. Harrison, M.D.
- Independent Director
- 568.56K
- Dr. Judy Chou, PhD
- Independent Director
- 571.06K
- Dr. Yuan Xu, PhD
- Independent Director
- 573.56K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data